GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Cyclically Adjusted PB Ratio

AEterna Zentaris (AEterna Zentaris) Cyclically Adjusted PB Ratio : 0.03 (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted PB Ratio?

As of today (2024-05-14), AEterna Zentaris's current share price is $8.36. AEterna Zentaris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $325.29. AEterna Zentaris's Cyclically Adjusted PB Ratio for today is 0.03.

The historical rank and industry rank for AEterna Zentaris's Cyclically Adjusted PB Ratio or its related term are showing as below:

AEZS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.97
Current: 0.02

During the past years, AEterna Zentaris's highest Cyclically Adjusted PB Ratio was 0.97. The lowest was 0.01. And the median was 0.06.

AEZS's Cyclically Adjusted PB Ratio is ranked better than
97.36% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs AEZS: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AEterna Zentaris's adjusted book value per share data for the three months ended in Dec. 2023 was $14.989. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $325.29 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted PB Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 - 0.12 0.02 0.02

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted PB Ratio falls into.



AEterna Zentaris Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AEterna Zentaris's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.36/325.29
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEterna Zentaris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=14.989/125.4675*125.4675
=14.989

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Book Value per Share CPI Adj_Book
201403 2,907.434 98.604 3,699.523
201406 1,770.121 99.473 2,232.686
201409 1,130.382 99.394 1,426.905
201412 2,211.298 98.367 2,820.517
201503 2,249.558 99.789 2,828.424
201506 516.018 100.500 644.211
201509 235.649 100.421 294.422
201512 217.696 99.947 273.282
201603 164.135 101.054 203.789
201606 91.056 102.002 112.004
201609 32.514 101.765 40.087
201612 48.088 101.449 59.473
201703 38.963 102.634 47.631
201706 27.877 103.029 33.948
201709 -11.891 103.345 -14.436
201712 -16.927 103.345 -20.551
201803 70.378 105.004 84.093
201806 57.843 105.557 68.754
201809 45.070 105.636 53.531
201812 11.599 105.399 13.808
201903 -21.653 106.979 -25.395
201906 -18.206 107.690 -21.211
201909 -10.968 107.611 -12.788
201912 -12.319 107.769 -14.342
202003 7.187 107.927 8.355
202006 3.948 108.401 4.570
202009 24.168 108.164 28.034
202012 21.077 108.559 24.360
202103 52.969 110.298 60.254
202106 50.576 111.720 56.800
202109 49.364 112.905 54.857
202112 43.647 113.774 48.133
202203 43.789 117.646 46.700
202206 44.724 120.806 46.450
202209 40.708 120.648 42.334
202212 29.470 120.964 30.567
202303 25.707 122.702 26.286
202306 23.954 124.203 24.198
202309 21.646 125.230 21.687
202312 14.989 125.468 14.989

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (NAS:AEZS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AEterna Zentaris Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.